COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024

08/11/2024 - 18:00

Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

08/11/2024 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

Pearson Medical Technologies Introduces m:Print Bar Code Labeling Software v4 for Pharmacy Drug Supply Chain Security Act (DSCSA) Compliance

08/11/2024 - 18:23

ALEXANDRIA, La., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Pearson Medical Technologies announces the international release of m:Print® Bar Code Labeling Software Version 4 , a powerful new upgrade of its industry-leading [...]

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

08/11/2024 - 18:31

Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk WALTHAM, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company [...]

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

08/11/2024 - 19:30

Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and KEYTRUDA ® ( [...]

Extendicare Announces New $275 Million Senior Secured Credit Facility

08/11/2024 - 20:18

MARKHAM, Ontario, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that it has entered into a new senior secured credit facility for $275.0 million (the “ [...]

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

08/11/2024 - 21:36

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

08/11/2024 - 21:47

Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of [...]

Novo Nordisk A/S - share repurchase programme

08/11/2024 - 21:51

Bagsværd, Denmark, 8 November 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase [...]

Aptose Reports Results for the Third Quarter 2024

08/11/2024 - 22:01

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ [...]

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08/11/2024 - 22:01

WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

08/11/2024 - 22:01

ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join [...]

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

08/11/2024 - 22:01

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation Off-the-shelf Product Candidate Incorporates Novel Sword & [...]

PacBio to Present at Upcoming Investor Conferences

08/11/2024 - 22:05

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the [...]

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

08/11/2024 - 22:05

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and [...]

Vera Therapeutics to Participate at Upcoming Investor Conferences

08/11/2024 - 22:05

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]

Codexis Announces New Employment Inducement Grants

08/11/2024 - 22:05

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an [...]

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

08/11/2024 - 22:15

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric [...]

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

08/11/2024 - 22:22

Bagsværd, Denmark, 8 November 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]